### Montelukast adult PBPK model

Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene 'CysLT' receptor 1', used in the maintenance treatment of asthma. Montelukast is mainly metabolized by CYP2C8 (72%) [1].  Montelukast is a strongly lipophilic drug. The final lipophilicity was estimated to be lower than the reported values, as with lipophilicity values above 3-4 the drug already reached maximal permeability levels. The final montelukast model applies metabolism by CYP2C8, and minor involved enzymesCYP3A4/5 (16% ) CYP2C9 (12%) and glomerular filtration [1-3] and adequately described the pharmacokinetics of montelukast in adults.

The montelukast model was developed using data of the following publications:

- Bovill JG, Sebel PS, Blackburn CL, Oei-Lim V, Heykants JJ. The pharmacokinetics of sufentanil in surgical patients. Anesthesiology. 1984 Nov;61(5):502-6. (https://www.ncbi.nlm.nih.gov/pubmed/6238552)
- Knorr B, Holland S, Rogers JD, Nguyen HH, Reiss TF. Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections. J Allergy Clin Immunol. 2000 Sep;106(3 Suppl):S171-8.
(https://www.ncbi.nlm.nih.gov/pubmed/10984399)
- Zhao JJ, Rogers JD, Holland SD, Larson P, Amin RD, Haesen R, Freeman A, Seiberling M, Merz M, Cheng H. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers.Biopharm Drug Dispos. 1997 Dec;18(9):769-77.
(https://www.ncbi.nlm.nih.gov/pubmed/9429741)
- Fey C, Thyroff-Friesinger U, Jones S. Bioequivalence of two formulations of montelukast sodium 4 mg oral granules in healthy adults. Clin Transl Allergy. 2014 Sep 18;4:29. doi: 10.1186/2045-7022-4-29. eCollection 2014.
https://www.ncbi.nlm.nih.gov/pubmed/25250173
- Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N, Rogers JD, Malbecq W, Meisner D, Somers G. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res. 1996 Mar;13(3):445-8.
https://www.ncbi.nlm.nih.gov/pubmed/8692739

### References
[1] Marzolini C, Rajoli R, Battegay M, Elzi L, Back D, Siccardi M. Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. Clin Pharmacokinet. 2017 Apr;56(4):409-420. doi: 10.1007/s40262-016-0447-7.

[2] Filppula AM, Laitila J, Neuvonen PJ, Backman JT. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. Drug Metab Dispos. 2011 May;39(5):904-11. doi: 10.1124/dmd.110.037689. Epub 2011 Feb 2.

[3] Zhou W, Johnson TN, Bui KH, Cheung SYA, Li J, Xu H, Al-Huniti N, Zhou D. Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children. Clin Pharmacol Ther. 2018 Jul;104(1):188-200. doi: 10.1002/cpt.905. Epub 2017 Nov 20.

The compound properties used for input are illustrated below.